Eytan Stein, MD

Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).

Stein says all patients with AML have a multitude of mutations that are causing their disease, and that targeting single mutations such as FLK3 and IDH may not be enough to make an impact. He adds that combining agents that, for example, target both of those mutations could very well be the future of the treatment paradigm.

Videos

Eytan Stein, MD, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).

Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia

Eytan Stein, MD, hematologist/oncologist, Memorial Sloan Kettering Cancer Center, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations. Stein says historically, oncologists have been giving induction chemotherapy and consolidation chemotherapy, which he says is non-specific and does an "okay job" at initially benefitting patients with acute myeloid leukemia before relapse.

Stein cites a recent phase III trial researching the drug midostaurin (PKC412), which inhibits FLK3, in combination with chemotherapy versus chemotherapy alone. He says the overall survival advantage of the combination is about 7% of 5 years, which is proof of principle for oncologists to begin considering the combination in their treatment paradigms.

Eytan Stein, MD, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations.

Eytan Stein, MD | Authors

Articles

Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia

Dr. Eytan Stein on Targeting Mutations in Acute Myeloid Leukemia